Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Tomatoes could prove to be a source of Parkinson’s drug L-DOPA

By Brian Buntz | December 15, 2020

Genetically modified tomato could serve as a source of L-DOPA

This genetically modified tomato could serve as a source of L-DOPA. Image courtesy of Phil Robinson. 

Researchers at the John Innes Centre in the U.K. have created a genetically modified tomato that serves as a source for the amino acid l-3,4-dihydroxyphenylalanine (L-DOPA), which the brain converts into dopamine. 

The discovery could provide an affordable source for the medicine, which first hit the market in the 1960s. Then touted as a “miracle drug,” L-DOPA showed promise for its ability to rouse patients who had been immobilized for years by Parkinson’s. 

But access to the drug, which the World Health Organisation classifies as an essential medicine, is limited in developing nations. 

The tomato-based source of L-DOPA could give more patients access to it globally. The cost of synthetic L-DOPA, roughly $2 daily, is prohibitive in many parts of the world. 

The scientists were able to produce 150 mg of L-DOPA per kilogram of tomatoes.  

The breakthrough could also benefit patients who suffer from L-DOPA side effects such as nausea and behavior disturbances. 

The researchers at the John Innes Centre modified the tomato plant by incorporating a gene linked to L-DOPA synthesis in beets. In beetroot, the gene is responsible for producing betalains, a group of tyrosine-derived red and yellow pigments. 

The source of L-DOPA is tyrosine, an amino acid found in several foods. 

L-DOPA itself was first isolated in 1913 from broad beans (Vicia faba). 

The velvet bean, Mucuna pruriens, is a more concentrated source of L-DOPA, containing up to 10% of the drug in its seeds, but the tropical legume is a problematic drug source. Velvet beans are difficult to harvest and contain high levels of tryptamines that can trigger hallucinations in patients with Parkinson’s disease.  

 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE